study reported no difference in circulating RBP4 levels between lean and obese women [5] , a finding confirmed very recently [6] . Furthermore, subcutaneous adipose tissue from obese women was characterised by lower RBP4 production compared with lean controls [5] . In these adipose tissue biopsies, GLUT4 levels correlated with RBP4 concentration, making it more likely that RBP4 levels positively correlate with insulin sensitivity in this study. Data on RBP4 production and regulation in human adipocytes are not available, and so the contribution of adipocytes to adipose tissue RBP4 output is difficult to evaluate.
In the present study, primary human preadipocytes were isolated from mammary adipose tissue samples of normal or moderately overweight women (age 40.5±3.8 years, BMI 24.2±2.7 kg/m 2 , n=4 in each group) undergoing surgical mammary reduction. All subjects were healthy, free of medication and had no evidence of diabetes according to routine laboratory tests. Adipose tissue samples were dissected from other tissues, pieces of ∼10 mg in weight were minced and preadipocytes were isolated by collagenase digestion as previously described [7] . Isolated preadipocytes were seeded in DMEM/Hams F12 medium supplemented with 10% fetal calf serum and kept in culture overnight. Adipocytes were differentiated over 15 days in a differentiation medium (DMEM/F12, 33 μmol/l biotin, 17 μmol/l D-pantothenic acid, 66 nmol/l insulin, 1 nmol/l triiodo-L-thyronine, 100 nmol/l cortisol, 10 μg/ml apotransferrin, 50 μg/μl gentamicin, 15 mmol/l HEPES, 14 mmol/l NaHCO 3 , pH 7.4). After 15 days of culture, 60-80% of cells were differentiated as defined by cytoplasm filled with small or large lipid droplets. Differentiated adipocytes were treated with recombinant human adiponectin (Tebu, Offenbach, Germany), troglitazone and recombi-nant human TNF-a (Sigma, Taufkirchen, Germany), and then the cells were lysed in 50 mmol/l HEPES containing 1% (vol/vol) Triton. Aliquots of 8 μg of protein were separated by SDS-PAGE and immunoblotted with antibodies directed against RBP4 (Alexis Biochemicals, Lausen, Switzerland), GLUT4 (Cell Signaling Technology, Frankfurt, Germany), peroxisome proliferator-activated receptor γ (PPARγ; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and tubulin (Calbiochem, Merck Biosciences, Schwalbach, Germany). Horseradish peroxidase-conjugated goat antirabbit and goat anti-mouse IgG antibodies were supplied by Promega (Mannheim, Germany). Statistical analysis was performed using Statview software (SAS, Cary, NC, USA), and a p value of <0.05 was considered statistically significant.
Primary human adipocytes produce RBP4 at levels of approximately 5 ng/μg of total cellular protein based on comparison with a recombinant RBP4 standard (data not shown). A very recent publication demonstrates that the RBP4 concentration is very low in isolated human preadipocytes but strongly increases during differentiation into mature adipocytes [6] . Here, we show that production of this adipokine is regulated by TNF-α and the PPARγ agonist troglitazone (Fig. 1a) . RBP4 production is not influenced by adiponectin, although adiponectin strongly influences the secretory function of primary adipocytes [7] . Our results show that TNF-a strongly downregulates RBP4 production in adipocytes, a completely unexpected effect, as TNF-a-treated adipocytes are insulin resistant [8] . Furthermore, troglitazone increases RBP4 levels by over 100%. This finding is in contrast to observations in mice, where rosiglitazone decreased Rbp4 mRNA expression in adipose tissue [1] . It may be speculated that the observed effect of troglitazone in mouse adipose tissue could be due to non-adipocytes. In addition to RBP4, troglitazone significantly stimulated the production of GLUT4 and PPARγ (Fig. 1b,c) . When applied overnight, TNF-α did not change GLUT4 production but significantly reduced PPARγ production. GLUT4 downregulation is known to require at least 24 h of TNF-a treatment, but insulin resistance can be observed as soon as 60 min after TNF-α administration in human adipocytes [8] .
The adipokine RBP4 has recently been shown to link obesity and insulin resistance in rodents [2] . In humans, however, the role of RBP4 is still controversial. In human adipocytes, RBP4 production is downregulated by the proinflammatory cytokine TNF-a, which is clearly linked to adipocyte insulin resistance [8] . In a very recent study, secretion of RBP4 and other pro-inflammatory cytokines was downregulated by atrial natriuretic peptide (ANP) [9] . ANP stimulates lipolysis in adipocytes and in humans [10] , an effect that can also be attributed to TNF-a. It might be that RBP4 production in adipocytes is linked to lipolysis. On the other hand, we found that troglitazone strongly induces RBP4 production in human adipocytes, a finding in contrast to data on adipose tissue of mice treated with the PPARγ agonist rosiglitazone [1] . However, the rosiglitazone-induced decreased in RBP4 in mice may reflect improved insulin sensitivity and may not represent the underlying causative effect. Taken together, our data suggest that RBP4 seems to correlate positively with insulin sensitivity and not with insulin resistance in isolated human adipocytes. The present experiments were carried out with adipocytes from mammary fat, which are more similar to subcutaneous adipocytes than to visceral ones. Interestingly, another study working with subcutaneous adipose tissue also revealed controversial data on RBP4 expression, showing that RBP4 mRNA expression is decreased in obese women compared with lean controls [5] . Our results point to an important difference in the regulation of RBP4 production between humans and rodents, as well as possible differences between fat depots. The contribution of RBP4 from adipocytes to circulating levels of this adipokine should be evaluated in diabetic and obese patients. The role of RBP4 as a pro-inflammatory adipokine may have to be revised.
